Table 1. Application of DigiPico sequencing and MutLX analysis to a diverse set of clinical samples.
| Run ID | Patient ID | Sample type | Collection site | Sequencing platform | Total UTD | Passed UTDs | Validation rate* | AUC |
|---|---|---|---|---|---|---|---|---|
| D1110 | #11152 | Recurrence | PT2R | NextSeq | 1634 | 4b | NA | 0.95 |
| D1111 | #11152 | Recurrence | PT2R | NextSeq | 1325 | 266 | 240/266c | 0.85 |
| D1112* | #11152 | Recurrence | PT2R | HiSeq 4000 | 1219 | 210 | 189/210c | 0.85 |
| D1511 | #11152 | Recurrence | PALNR | HiSeq X | 1786 | 9 | NA | 0.94 |
| D1210 | #11152 | Pre-chemo | OM | NextSeq | 3139 | 28 | 16/28c | 0.94 |
| D1211 | #11152 | Pre-chemo | OM | HiSeq 4000 | 5521 | 69 | 17/69c | 0.91 |
| D1212 | #11152 | Pre-chemo | OM | HiSeq 4000 | 5015 | 24 | 16/24c | 0.94 |
| D1213 | #11152 | Pre-chemo | OM | HiSeq 4000 | 5090 | 46 | 25/46c | 0.93 |
| D1214 | #11152 | Pre-chemo | OM | HiSeq 4000 | 3415 | 37 | 27/37c | 0.93 |
| DE011 | #11513 | Normal | Blood | HiSeq X | 1759 | 7b | NA | 0.95 |
| DE111 | #11513 | Pre-chemo | Ascites | HiSeq X | 3685 | 4b | NA | 0.97 |
| D6311 | OP1036 | Pre-chemo | RPCG | HiSeq X | 3185 | 12 | NA | 0.96 |
| DA111 | #11502 | Pre-chemo | LPrt | NextSeq | 12511 | 10 | NA | 0.97 |
| GM12885 | - | Cell line | - | NextSeq | 2970 | 3b | NA | 0.96 |
* Run D1112 is a technical replicate of run D1111. b Runs where true UTDs are not expected to be present.c Validation through comparison with independent high-depth WGS data from the bulk of the tumor. * Validation rate is an under-estimation for the positive predictive value of clone-specific variants. PT2R: Pelvic Tumor Recurrence; PALNR: Para-Aortic Lymph Node Recurrence; OM: Omental Mass; RPCG: Right Paracolic Gutter; LPrt: Left Peritoneum; NA: Not Available; AUC: Area Under the Curve of receiver operating characteristic plot.
The study of active mutational processes using DigiPico/MutLX.